GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » ROC (Joel Greenblatt) %

CING (Cingulate) ROC (Joel Greenblatt) % : -541.86% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cingulate ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cingulate's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -541.86%.

The historical rank and industry rank for Cingulate's ROC (Joel Greenblatt) % or its related term are showing as below:

CING' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -643.73   Med: -402.44   Max: -173.69
Current: -601.44

During the past 5 years, Cingulate's highest ROC (Joel Greenblatt) % was -173.69%. The lowest was -643.73%. And the median was -402.44%.

CING's ROC (Joel Greenblatt) % is ranked worse than
60.96% of 1401 companies
in the Biotechnology industry
Industry Median: -312.08 vs CING: -601.44

Cingulate's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cingulate ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cingulate's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate ROC (Joel Greenblatt) % Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-280.04 -173.69 -484.40 -402.44 -643.73

Cingulate Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -747.00 -924.60 -415.14 -476.82 -541.86

Competitive Comparison of Cingulate's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Cingulate's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cingulate's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cingulate's ROC (Joel Greenblatt) % falls into.


;
;

Cingulate ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.518) - (1.713 + 0 + 0)
=-1.195

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.302) - (1.308 + 0 + 0.00099999999999989)
=-0.0070000000000003

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cingulate for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-13.132/( ( (2.611 + max(-1.195, 0)) + (2.236 + max(-0.0070000000000003, 0)) )/ 2 )
=-13.132/( ( 2.611 + 2.236 )/ 2 )
=-13.132/2.4235
=-541.86 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate  (NAS:CING) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cingulate ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cingulate's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cingulate Business Description

Traded in Other Exchanges
N/A
Address
1901 West 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Executives
Laurie Myers officer: EVP & Chief Operating Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Jennifer L. Callahan officer: Corporate Controller C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth director, 10 percent owner C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer director, 10 percent owner, officer: Chief Executive Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon officer: EVP & General Counsel C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum director C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros director 2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G officer: EVP & Chief Financial Officer C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva officer: EVP & Chief Science Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams officer: EVP & Chief Medical Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc 10 percent owner 1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205